Are There Peptide Protocols for Perimenopausal Women?

Perimenopause is not what most people think it is, and that misunderstanding is exactly why so many women end up on the wrong protocol.

The common assumption is that perimenopause means estrogen drops and everything falls apart from there. What actually happens is more complicated, and it matters because the sequence of events determines what you should do first.

Progesterone is the first hormone to fall. This happens because your ovaries stop releasing an egg every cycle with the same regularity they once did, and without ovulation, there is no corpus luteum, which is the temporary structure that forms after ovulation and is responsible for producing progesterone. No ovulation, no corpus luteum, no progesterone. The process is that direct.

Estrogen does not simply decline alongside it. Research published by Santoro and colleagues in the Journal of Clinical Endocrinology and Metabolism showed that estrogen during perimenopause actually becomes erratic, spiking higher than levels seen in a woman's twenties before crashing and then spiking again. So what you end up with is a system where progesterone has fallen but estrogen is swinging unpredictably, and the ratio between the two is broken.

That broken ratio is what is driving the symptoms. The disrupted sleep, the visceral fat accumulating around the midsection without any changes to diet or training, the anxiety, the changes in body composition that feel completely disconnected from anything the woman is actually doing. These are not random. They are the downstream consequences of that ratio being off.

So the starting point is not peptides. The starting point is addressing the actual deficiency, which is progesterone.

A 2023 Phase III randomized controlled trial published in Scientific Reports looked specifically at oral micronized progesterone versus placebo and found that progesterone improved sleep quality and reduced night sweats. This matters because sleep disruption and temperature dysregulation are often the first symptoms perimenopausal women report, and both of them trace back to this same hormonal imbalance rather than estrogen deficiency specifically.

What you do not do is add estrogen first. If the ovaries are still producing estrogen unpredictably, layering exogenous estrogen on top of that creates additional instability rather than fixing anything. The question of when to introduce estrogen depends on where the woman actually is in the transition, and there is a specific marker that helps answer that.

Something called anti-Mullerian hormone, which is a signal produced by the follicles in the ovaries that reflects how much ovarian reserve remains, can tell you how far along that transition has progressed. The Penn Ovarian Aging Study, a 14-year longitudinal study of 401 women published by Freeman and colleagues in 2012, showed that AMH predicts menopause timing with meaningful accuracy. When AMH becomes essentially undetectable and a woman has gone 12 consecutive months without a period, that is menopause, and that is the appropriate point at which estrogen replacement enters the picture.

Now, where do peptides fit into this?

The honest answer is that they fit as a second layer, not a foundation. What they can do is manage specific downstream symptoms that the hormonal imbalance creates. There are three systems they can meaningfully influence.

The first is the metabolic system. Peptides like tirzepatide or retatrutide work on receptors involved in appetite regulation and metabolic rate, which helps address both the weight changes and what is often described as food noise, the constant cognitive preoccupation with eating that becomes harder to override when metabolic hormones are dysregulated.

The second is sleep and anxiety. Peptides like Selank, which acts on the GABA and serotonin systems to reduce anxious arousal, or DSIP, which is short for delta sleep-inducing peptide and does what the name suggests by promoting deeper sleep architecture, can provide some relief for two of the most disruptive symptoms perimenopausal women experience.

The third is the growth hormone axis. Secretagogues like tesamorelin or CJC-1295 work by stimulating the pituitary gland to release more growth hormone, which then drives the production of something called IGF-1, the actual downstream signal that produces most of the body composition and recovery benefits associated with growth hormone. The issue is that this entire axis depends on estrogen being present and stable.

This is where the research becomes very specific. A study by Shah and colleagues published in the Journal of Clinical Endocrinology and Metabolism in 2019 looked directly at how estrogen status affects pituitary response to growth hormone secretagogues. The finding, with a p-value of 0.001, was that pulsatile growth hormone secretion is significantly blunted without estradiol. Estrogen is what allows the pituitary to respond properly to GHRH, the signal that tells it to release growth hormone in the first place. Remove estrogen from that equation and the secretagogue is pushing on a door that will not fully open.

This is the practical problem with jumping straight to growth hormone peptides in a perimenopausal woman who has not addressed her hormonal status. The protocol is not wrong in concept. The timing is wrong. You are trying to optimize a system that is operating with a missing input.

The sequencing, then, is what determines whether any of this actually works. Progesterone first, because it is the actual deficiency driving most of the early perimenopausal symptoms. AMH testing to understand where in the transition the woman is, so the decision about when to introduce estrogen is based on data rather than guessing. Estrogen when the transition is complete and the ovaries are no longer producing it unpredictably. And then, once estrogen levels are stable, the growth hormone secretagogues will actually be able to do what they are designed to do, because the pituitary will have what it needs to respond.

Peptides are tools. But a tool used out of sequence in a system that is missing a foundational input is just adding complexity without adding benefit.

The women who get the most out of peptide protocols are the ones who came to them after the hormonal foundation was already in place. The peptides did not fix their perimenopause. The hormones did. The peptides just helped them optimize what was already working.

---

References

1. Santoro et al., 2004, Journal of Clinical Endocrinology & Metabolism — progesterone declines before estrogen, estrogen becomes erratic during perimenopause
2. Freeman et al., 2012, Journal of Clinical Endocrinology & Metabolism — AMH predicts menopause timing (Penn Ovarian Aging Study, 401 women, 14 years)
3. Prior, 2014, Facts, Views & Vision in ObGyn — progesterone as appropriate first-line therapy for perimenopause
4. Shah et al., 2019, Journal of Clinical Endocrinology & Metabolism — pulsatile GH secretion significantly blunted without estradiol (P = 0.001), estrogen potentiates pituitary GHRH response
5. Prior et al., 2023, Scientific Reports — Phase III RCT, oral micronized progesterone improved sleep quality and reduced night sweats vs placebo

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness